Practical Analytical and Clinical Validation Strategies for Cell-Free Tumor DNA Assays

Enroll

This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, and a post-test.

CME and CMLE credits are not available for this webinar.

This interactive webinar is part 2 of the 8-part Utility of Cell-Free DNA in the Clinic Series.

Description:

There is increasing adoption of circulating tumor DNA (ctDNA) assays in molecular oncology. Ensuring that technical and compliance requirements for clinical lab testing are met can be particularly challenging for ctDNA assays. This presentation will include discussion of analytical validation strategies for ctDNA assays to establish that assays perform as intended.

Learning Objectives:

1.       Define cell-free DNA (cfDNA), and recognize its dynamics in health and disease.
2.       Understand challenges unique to cfDNA assay validation.
3.       Identify solutions for analytically validating cfDNA assays.
4.       Discuss opportunities and limitations for assessing circulating tumor DNA (ctDNA) in oncology.


Speaker: Christina Lockwood, MD	Moderator: Meera Hameed, MD

Recording Date: July 27, 2021
Duration: 1 hr
Level of Instruction: Basic

Continuing Education Credit Information

CME and CMLE credits are not available for this webinar.

Supported by an educational grant from AstraZeneca

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation

Enroll